Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials

BMC Medicine

C Mary Schooling²  Benjamin J Cowling¹  Guy Freeman¹  Lin Xu¹ 

[1] School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China;CUNY School of Public Health at Hunter College, 2180 Third Avenue, New York, NY, 10035, USA

关键词: Trial;    Men;    Cardiovascular;    Testosterone;   

Others  :  857088
DOI  :  10.1186/1741-7015-11-108

 received in 2012-12-17, accepted in 2013-03-15,  发布年份 2013

【 摘 要 】

Background

Testosterone therapy is increasingly promoted. No randomized placebo-controlled trial has been implemented to assess the effect of testosterone therapy on cardiovascular events, although very high levels of androgens are thought to promote cardiovascular disease.

Methods

A systematic review and meta-analysis was conducted of placebo-controlled randomized trials of testosterone therapy among men lasting 12+ weeks reporting cardiovascular-related events. We searched PubMed through the end of 2012 using “(“testosterone” or “androgen”) and trial and (“random*”)” with the selection limited to studies of men in English, supplemented by a bibliographic search of the World Health Organization trial registry. Two reviewers independently searched, selected and assessed study quality with differences resolved by consensus. Two statisticians independently abstracted and analyzed data, using random or fixed effects models, as appropriate, with inverse variance weighting.

Results

Of 1,882 studies identified 27 trials were eligible including 2,994, mainly older, men who experienced 180 cardiovascular-related events. Testosterone therapy increased the risk of a cardiovascular-related event (odds ratio (OR) 1.54, 95% confidence interval (CI) 1.09 to 2.18). The effect of testosterone therapy varied with source of funding (P-value for interaction 0.03), but not with baseline testosterone level (P-value for interaction 0.70). In trials not funded by the pharmaceutical industry the risk of a cardiovascular-related event on testosterone therapy was greater (OR 2.06, 95% CI 1.34 to 3.17) than in pharmaceutical industry funded trials (OR 0.89, 95% CI 0.50 to 1.60).

Conclusions

The effects of testosterone on cardiovascular-related events varied with source of funding. Nevertheless, overall and particularly in trials not funded by the pharmaceutical industry, exogenous testosterone increased the risk of cardiovascular-related events, with corresponding implications for the use of testosterone therapy.

【 授权许可】

   
2013 Xu et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA: Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011, 96:3007-3019.
• [2]Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM: Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011, 97:870-875.
• [3]Sartorius G, Spasevska S, Idan A, Turner L, Forbes E, Zamojska A, Allan CA, Ly LP, Conway AJ, McLachlan RI, Handelsman DJ: Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol (Oxf) 2012, 77:755-763.
• [4]Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N: Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 2010, 60:194-201.
• [5]Jones TH: Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab 2010, 21:496-503.
• [6]Traish AM, Saad F, Feeley RJ, Guay A: The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009, 30:477-494.
• [7]Eggertson L: Brouhaha erupts over testosterone-testing advertising campaign. CMAJ 2011, 183:E1161-E1162.
• [8]Morgentaler A: Testosterone for Life. New York: McGraw-Hill; 2008.
• [9]Sexual dysfunction as the last bastion of urological drug commercialisation within the pharmaceutical industry BJU Int 2011, 107:1845-1846.
• [10]Handelsmann DJ: Pharmacoepidemiology of testosterone prescribing in Australia, 1992–2010. Med J Aust 2012, 196:642-645.
• [11]Gan EH, Pattman S, Pearce S, Quinton R: Many men are receiving unnecessary testosterone prescriptions. BMJ 2012, 345:e5469.
• [12]Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy: TESTOSTERONE AND AGING Clinical Research Directions. Washington: The National Academies Press; 2004.
• [13]Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S: Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005, 60:1451-1457.
• [14]Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM: Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007, 82:29-39.
• [15]Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM: Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 95:2560-2575.
• [16]Schooling C, Xu L, Freeman G, Cowling B: Testosterone and cardiovasclar related events in men: a meta-analysis of randomized controlled trials. PROSPERO 2011:CRD42011001815 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42011001815 webcite
• [17]Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ, Strom BL: Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999, 84:2647-2653.
• [18]Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL: Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999, 84:1966-1972.
• [19]Snyder PJ, Peachey H, Berlin JA, Rader D, Usher D, Loh L, Hannoush P, Dlewati A, Holmes JH, Santanna J, Strom BL: Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med 2001, 111:255-260.
• [20]Tugwell P, Judd MG, Fries JF, Singh G, Wells GA: Powering our way to the elusive side effect: a composite outcome ‘basket’ of predefined designated endpoints in each organ system should be included in all controlled trials. J Clin Epidemiol 2005, 58:785-790.
• [21]Singh S, Loke YK, Spangler JG, Furberg CD: Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011, 183:1359-1366.
• [22]Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG: The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998, 51:1235-1241.
• [23]Doshi P, Jones M, Jefferson T: Rethinking credible evidence synthesis. BMJ 2012, 344:d7898.
• [24]Ioannidis JP: Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 2009, 169:1737-1739.
• [25]Pitrou I, Boutron I, Ahmad N, Ravaud P: Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009, 169:1756-1761.
• [26]Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, Mazer NA, Knapp PE, Hanka S, Lakshman KM, Ulloor J, Zhang A, Orwoll K, Eder R, Collins L, Mohammed N, Rosen RC, DeRogatis L, Bhasin S: Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med 2012, 157:681-691.
• [27]Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M: Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011, 165:687-701.
• [28]Cattabiani C, Basaria S, Ceda GP, Luci M, Vignali A, Lauretani F, Valenti G, Volpi R, Maggio M: Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest 2012, 35:104-120.
• [29]Carson CC 3rd, Rosano G: Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med 2012, 9:54-67.
• [30]Gullett NP, Hebbar G, Ziegler TR: Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 2010, 91:1143S-1147S.
• [31]Bain J: Testosterone and the aging male: to treat or not to treat? Maturitas 2010, 66:16-22.
• [32]McLaren D, Siemens DR, Izard J, Black A, Morales A: Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome. BJU Int 2008, 102:1142-1146.
• [33]Krause W, Mueller U, Mazur A: Testosterone supplementation in the aging male: which questions have been answered? Aging Male 2005, 8:31-38.
• [34]Kaufman JM, Vermeulen A: The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005, 26:833-876.
• [35]Kenny AM, Prestwood KM, Gruman CA, Fabregas G, Biskup B, Mansoor G: Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2002, 57:M460-M465.
• [36]Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ: Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003, 88:3167-3176.
• [37]Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG: Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001, 56:M266-M272.
• [38]Morley JE, Perry HM 3rd, Kaiser FE, Kraenzle D, Jensen J, Houston K, Mattammal M, Perry HM Jr: Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993, 41:149-152.
• [39]Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A, Eldh J, Sjostrom L, Holm G, Bjorntorp P: Androgen treatment of abdominally obese men. Obes Res 1993, 1:245-251.
• [40]Sullivan DH, Roberson PK, Johnson LE, Bishara O, Evans WJ, Smith ES, Price JA: Effects of muscle strength training and testosterone in frail elderly males. Med Sci Sports Exerc 2005, 37:1664-1672.
• [41]Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R: Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008, 20:378-387.
• [42]Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R: AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003, 88:2673-2681.
• [43]Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, McGee D: Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010, 58:1134-1143.
• [44]Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ: Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011, 8:2079-2089.
• [45]Frederiksen L, Hojlund K, Hougaard DM, Brixen K, Andersen M: Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr) 2012, 34:145-156.
• [46]Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM: Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 2009, 160:821-831.
• [47]Pugh PJ, Jones RD, West JN, Jones TH, Channer KS: Testosterone treatment for men with chronic heart failure. Heart 2004, 90:446-447.
• [48]Chapman IM, Visvanathan R, Hammond AJ, Morley JE, Field JB, Tai K, Belobrajdic DP, Chen RY, Horowitz M: Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr 2009, 89:880-889.
• [49]Testosterone treatment of men with alcoholic cirrhosis: a double-blind study: The Copenhagen Study Group for Liver Diseases. Hepatology 1986, 6:807-813.
• [50]Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S: Adverse events associated with testosterone administration. N Engl J Med 2010, 363:109-122.
• [51]Hall GM, Larbre JP, Spector TD, Perry LA, Da Silva JA: A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol 1996, 35:568-573.
• [52]Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C: Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997, 82:1661-1667.
• [53]English KM, Steeds RP, Jones TH, Diver MJ, Channer KS: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000, 102:1906-1911.
• [54]Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL: Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004, 89:503-510.
• [55]Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S: Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci 2004, 59:75-78.
• [56]Svartberg J, Aasebo U, Hjalmarsen A, Sundsfjord J, Jorde R: Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004, 98:906-913.
• [57]Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ: Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 2006, 47:251-262.
• [58]Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS: Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006, 27:57-64.
• [59]Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, Eastell R, Wu F, Ross RJ: Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl 2006, 29:381-391.
• [60]Nair KS, Rizza RA, O’Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla MC, Tindall DJ, Melton LJ 3rd, Smith GE, Khosla S, Jensen MD: DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006, 355:1647-1659.
• [61]Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT: Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008, 299:39-52.
• [62]Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM: Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009, 54:919-927.
• [63]Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G: Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010, 7:3495-3503.
• [64]Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, Wu FC: Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010, 95:639-650.
• [65]Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS: Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011, 34:828-837.
• [66]Ho CC, Tong SF, Low WY, Ng CJ, Khoo EM, Lee VK, Zainuddin ZM, Tan HM: A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 2012, 110:260-265.
• [67]Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F: Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010, 73:602-612.
• [68]Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY: Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 2012, 167:531-541.
• [69]Haring R, Teumer A, Volker U, Dorr M, Nauck M, Biffar R, Volzke H, Baumeister SE, Wallaschofski H: Mendelian randomization suggests non-causal associations of testosterone with cardiometabolic risk factors and mortality. Andrology 2013, 1:17-23.
• [70]Labrie F, Cusan L, Gomez JL, Martel C, Berube R, Belanger P, Belanger A, Vandenput L, Mellstrom D, Ohlsson C: Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 2009, 113:52-56.
• [71]Labrie F: Intracrinology. Mol Cell Endocrinol 1991, 78:C113-C118.
• [72]Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012, 13:983-992.
• [73]Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, De WR, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
• [74]The Coronary Drug Project: Findings leading to discontinuation of the 2.5-mg day estrogen group. The Coronary Drug Project Research Group. JAMA 1973, 226:652-657.
• [75]Basaria S, Davda MN, Travison TG, Ulloor J, Singh R, Bhasin S: Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 2013, 68:153-160.
• [76]Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L, Conway AJ, Handelsman DJ: Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Ann Intern Med 2010, 153:621-632.
• [77]Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS: The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab 2002, 87:1467-1472.
• [78]Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ: A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001, 86:4078-4088.
• [79]Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, Mazer NA, Ngyuen AH, Davda MN, Jara H, Aakil A, Anderson S, Knapp PE, Hanka S, Mohammed N, Daou P, Miciek R, Ulloor J, Zhang A, Brooks B, Orwoll K, Hede-Brierley L, Eder R, Elmi A, Bhasin G, Collins L, Singh R, Basaria S: Effect of testosterone supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA 2012, 307:931-939.
• [80]Ajayi AA, Mathur R, Halushka PV: Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 1995, 91:2742-2747.
• [81]Eyben FE, Graugaard C, Vaeth M: All-cause mortality and mortality of myocardial infarction for 989 legally castrated men. Eur J Epidemiol 2005, 20:863-869.
• [82]Swerdlow AJ, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA: Mortality in patients with Klinefelter syndrome in Britain: a cohort study. J Clin Endocrinol Metab 2005, 90:6516-6522.
• [83]Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011, 306:2359-2366.
• [84]Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, Mears D, Schemitsch EH, Heels-Ansdell D, Devereaux PJ: Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004, 170:477-480.
• [85]Gluud LL: Bias in clinical intervention research. Am J Epidemiol 2006, 163:493-501.
• [86]Petitti D: Commentary: hormone replacement therapy and coronary heart disease: four lessons. Int J Epidemiol 2004, 33:461-463.
• [87]Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M: Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract 2009, 15:289-305.
• [88]Shamlian NT, Cole MG: Androgen treatment of depressive symptoms in older men: a systematic review of feasibility and effectiveness. Can J Psychiatry 2006, 51:295-299.
• [89]Bolona ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, Caples SM, Erwin PJ, Montori VM: Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007, 82:20-28.
• [90]Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, Caples SM, Erwin PJ, Montori VM: Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006, 91:2011-2016.
• [91]Kong A, Edmonds P: Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002, 2:692-699.
• [92]Johns K, Beddall MJ, Corrin RC: Anabolic steroids for the treatment of weight loss in HIV-infected individuals. Cochrane Database Syst Rev 2005, 4:CD005483.
• [93]D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
• [94]Menke A, Guallar E, Rohrmann S, Nelson WG, Rifai N, Kanarek N, Feinleib M, Michos ED, Dobs A, Platz EA: Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol 2010, 171:583-592.
• [95]Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, Goldstein BA, Stirrups K, Konig IR, Cazier JB, Johansson A, Hall AS, Lee JY, Willer CJ, Chambers JC, Esko T, Folkersen L, Goel A, Grundberg E, Havulinna AS, Ho WK, Hopewell JC, Eriksson N, Kleber ME, Kristiansson K, Lundmark P, Lyytikainen LP: Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2012, 45:25-33.
• [96]Wieland LS, Robinson KA, Dickersin K: Understanding why evidence from randomised clinical trials may not be retrieved from Medline: comparison of indexed and non-indexed records. BMJ 2012, 344:d7501.
• [97]Ferreira ML, Herbert RD, Crowther MJ, Verhagen A, Sutton AJ: When is a further clinical trial justified? BMJ 2012, 345:e5913.
• [98]Pereira TV, Ioannidis JP: Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. J Clin Epidemiol 2011, 64:1060-1069.
• [99]LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F: Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997, 337:536-542.
• [100]Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM: Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2002, 57:M321-M325.
• [101]Marin P, Oden B, Bjorntorp P: Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995, 80:239-243.